Rating Change
Wedbush reiterated its Outperform rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on November 05, 2026.
reiterateNASDAQ:BCRX
Wedbush Reiterates Outperform Rating on BioCryst Pharmaceuticals, Inc. (BCRX)
Wedbush reiterated its Outperform rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on November 05, 2026.
At publication ·
What changed
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) · reiterate
- Firm
- Wedbush
- Rating
- Outperform to Outperform
- Price at event
- $7.61
- Market capitalization
- $1.6B
At a glance
Key takeaways
- Wedbush reiterated an Outperform rating on BioCryst Pharmaceuticals (BCRX) on November 5, 2026, with the stock trading at $7.61 and a market capitalization of $1.6 billion.
Market Context
BioCryst Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $7.61 with a market capitalization of $1.6B.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for BioCryst Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for BioCryst Pharmaceuticals, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 05, 2026 | Wedbush | Outperform | N/A |
| Sep 30, 2026 | JP Morgan | Neutral | N/A |
| Sep 10, 2026 | RBC Capital | Sector Perform | N/A |
| Sep 08, 2026 | Needham | Buy | N/A |
| Aug 06, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View BCRX Stock Page
Frequently Asked Questions
What does the Outperform rating mean for BCRX?
A rating of Outperform from Wedbush reflects the analyst's outlook on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BCRX forecast page.
